PMV Pharmaceuticals (NASDAQ:PMVP) and Silence Therapeutics (NASDAQ:SLN) Head-To-Head Survey

PMV Pharmaceuticals (NASDAQ:PMVP) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for PMV Pharmaceuticals and Silence Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1	0	1	0	2.00
Silence Therapeutics	2	0	4	0	2.33

PMV Pharmaceuticals currently has a consensus price target of $5.00, indicating a potential upside of 309.84%. Silence Therapeutics has a consensus price target of $32.60, indicating a potential upside of 468.94%. Given Silence Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than PMV Pharmaceuticals.

Earnings and Valuation

This table compares PMV Pharmaceuticals and Silence Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$58.71 million	($1.60)	-0.76
Silence Therapeutics	$43.26 million	6.26	-$45.31 million	($1.35)	-4.24

Silence Therapeutics has higher revenue and earnings than PMV Pharmaceuticals. Silence Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

PMV Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.

Institutional and Insider Ownership

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares PMV Pharmaceuticals and Silence Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-55.34%	-51.01%
Silence Therapeutics	-254.25%	-61.76%	-36.62%

Summary

Silence Therapeutics beats PMV Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.